ライフサイエンスコーパス: specific disease

1 or the adaptation of pathway signatures into specific disease.

2 spasticity, and dystonia, hallmarks of brain-specific disease.

3 ubiquitously expressed DYNC1H1 cause neuron-specific disease.

4 PTCL was not pathognomonic for any specific disease.

5 suggesting a link between systemic and site-specific disease.

6 ubiquitously expressed genes lead to retina-specific disease.

7 ery method to identify panels of markers for specific disease.

8 ion of multiple biomarkers associated with a specific disease.

9 evelopment as opposed to being assigned to a specific disease.

10 nction, and proposed that JNCL is a mutation-specific disease.

11 lamin A and emerin cause cardiac- or muscle-specific disease.

12 iven to randomized controlled trials of site-specific disease.

13 ly assess the value of an intervention for a specific disease.

14 entify targets that may be associated with a specific disease.

15 no convincing direct causal relation to any specific disease.

16 n no genes are known to be associated with a specific disease.

17 expressed RNA-binding proteins cause tissue specific disease.

18 he microbiome rather than connections with a specific disease.

19 values of quantitative traits or those with specific diseases.

20 se treatments into management strategies for specific diseases.

21 with these procedures can be associated with specific diseases.

22 position and its correlation with health and specific diseases.

23 fluenced by age, gender, and the presence of specific diseases.

24 que predictions concerning the etiologies of specific diseases.

25 f known cases of small molecules that target specific diseases.

26 mutations in NPC components result in tissue-specific diseases.

27 for stratifying individual risk profiles in specific diseases.

28 cept of importance in vaccine design against specific diseases.

29 relapsing-remitting EAE and other SJL strain-specific diseases.

30 predisposition to more than 80 human tissue-specific diseases.

31 rofiling of BRCA1 or other genes relevant to specific diseases.

32 therapies targeting the relevant isoform for specific diseases.

33 ids, and their application to modeling organ-specific diseases.

34 pressed in the kidney and are upregulated in specific diseases.

35 claimed to treat, prevent, diagnose, or cure specific diseases.

36 increased expression has been highlighted in specific diseases.

37 not make claims for the treatment or cure of specific diseases.

38 ique molecules for an autoimmune response in specific diseases.

39 ransposon activity during the development of specific diseases.

40 clinically efficacious drug combinations for specific diseases.

41 ty landscape that have potential relation to specific diseases.

42 f the maturation system, are associated with specific diseases.

43 oups to distinguish their individual role in specific diseases.

44 male offspring but little is known regarding specific diseases.

45 t pathogens, label cells/tissues, and report specific diseases.

46 associated with developmental syndromes and specific diseases.

47 rs, or different ones, of relevance to other specific diseases.

48 tic testing, contributes to the detection of specific diseases.

49 as a potential strategy to treat prelamin A-specific diseases.

50 y genes inside ClinVar are associated with a specific disease?

51 between anti-Jo-1 antibody levels and organ-specific disease activity in cross-sectional and longitu

52 nnaire (HAQ) score collected, and had the RA-specific Disease Activity Score performed by a rheumatol

53 Characterization of population-specific disease alleles may have important implications

54 se advances have already shown potential for specific, disease-altering therapies, and as our mechani

55 nsSNPs among multiple genes associated with specific diseases, anatomies, mammalian phenotypes, gene

56 m the health insurance system, and to region-specific disease and death registers.

57 nds beyond episodes of illness or care for a specific disease and is ongoing over time.

58 on prior methods and can suggest markers for specific disease and response stages that are not found

59 y associated changes that help predispose to specific diseases and also identifies novel windows of p

60 l toxicant that causes a wide range of organ-specific diseases and cancers.

61 ups that represented biological pathways for specific diseases and drugs.

62 ugs, few extensively synthesize pathways for specific diseases and drugs.

63 thylation patterns have been associated with specific diseases and environmental exposures, the media

64 we highlight some of these diverse and site-specific diseases and how they fit the DRF classificatio

65 Associations between specific diseases and HTLV-1 status were determined usin

66 ency, enhancing the diagnostic precision for specific diseases and reducing diagnostic cost.

67 variations that may affect susceptibility to specific diseases and that influence the pharmacokinetic

68 less is known about the end-of-life costs of specific diseases and the associated financial risk for

69 pact on how genetic variation contributes to specific diseases and traits by providing a compendium o

70 alpha2-Glia(63-71)-NH2, was able to identify specific disease antibodies with a sensitivity of 50% an

71 Specific diseases are definable, but mechanisms are poor

72 dual-acting modulator opportunities within a specific disease area.

73 o develop enhanced ability and experience in specific disease areas or procedures will benefit patien

74 and mouse-derived protocols identified human-specific disease aspects.

75 in-responsive megaloblastic anemia, a tissue-specific disease associated with diabetes mellitus, mega

76 Specific diseases associated with fecal incontinence inc

77 nt advances in nanomedicines that can target specific disease-associated cells.

78 ctivity and often-observed overexpression of specific disease-associated enzymes make them extremely

79 n subject will possess T cells responsive to specific disease-associated epitopes.

80 lysis of PDAC patient samples has shown that specific disease-associated mutations are correlated wit

81 tructures, perhaps each corresponding to the specific disease-associated protein with distinct conseq

82 damaging variants to identify new population-specific disease-associated rare/functional variants.

83 We aimed to identify the specific disease-associated variants in this locus, and

84 platform to detect easily quantifiable, site-specific, disease-associated glycan alterations for clin

85 To prioritize lineage-specific, disease-associated lncRNA expression, we emplo

86 igning clinical trials and assessing malaria-specific disease associations.

87 We compared rates of serotype-specific disease before and after PCV7 was licensed for

88 e our approach, which increasingly relies on specific disease biology.

89 ned antibodies are used for the detection of specific disease biomarker proteins in buffer and in com

90 accessible in biological fluids and contain specific disease biomarkers, making them attractive for

91 and disease, and for the development of age-specific disease biomarkers.

92 tal stage of life exacerbated not only organ-specific diseases but also systemic autoimmune diseases.

93 enes and processes that predispose organs to specific diseases can be identified using gene expressio

94 The new method successfully predicts the specific disease caused by a gene variant and ranks its

95 ity to cure and prevent disease, to identify specific disease causes (microbes), and to deal with div

96 tential for targeted therapy directed at the specific disease-causing abnormality.

97 To understand pathophysiology, the specific disease-causing gene(s) within each CNV need to

98 ructs for gene therapy) that are tailored to specific disease-causing mutants of CFTR.

99 with the creation and inclusion of pediatric-specific disease characteristics in the most recent WHO

100 hile future work is required to identify the specific disease characteristics that correspond to pati

101 mer disease (AD) has been considered a brain-specific disease characterized by the presence of Abeta

102 Incorporating race-specific disease comorbidity patterns will produce a mor

103 need for rapid disease control, presence of specific disease complications, and patient's age.

104 on our understanding of the pathogenesis of specific disease conditions after renal transplantation,

105 obal regulation and stress response to study specific disease conditions and identification of drug t

106 ing where related actions of CLA converge in specific disease conditions and physiologic states is ho

107 anatomy, neurophysiology, pathophysiology in specific disease conditions, autonomic testing, risk str

108 species (HAdV-A to -G), each associated with specific disease conditions.

109 es and sub-cellular locations, perhaps under specific disease conditions.

110 er of authors and representation of women in specific diseases, countries, continents, year, and spec

111 rectum, and age of diagnosis associated with specific disease course and therapeutic response.

112 Because of cancer's high symptom burden and specific disease course, patients with cancer are more l

113 In the context of cancer, tumours may have specific disease-defining mutations, but a patient's ger

114 oducts can treat, prevent, diagnose, or cure specific diseases, despite regulations prohibiting such

115 nly 14.6% of the patients did never have any specific disease diagnosed before graft loss.

116 body areas, is a clinical sign rather than a specific disease diagnosis.

117 ntives and mortality needs to be assessed in specific disease domains.

118 of prematurity, but rather caused by either specific disease during intensive care or factors operat

119 Although fish consumption may reduce specific disease endpoints, such as sudden cardiac death

120 m of platelet microparticle participation in specific disease entities such as rheumatoid arthritis h

121 e following five pathogenic types, each with specific disease entities: immune-complex GN, pauci-immu

122 opportunities, perceived needs and barriers, specific disease examples, and recommendations on facili

123 teins the active MMP forms important for the specific disease for identification.

124 The actuarial 5-year overall, disease-specific, disease-free, and distant metastasis-free surv

125 zed for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide

126 cal phenotypes that can be associated with a specific disease gene, as well as the complexity of the

127 ranscriptomes and may represent novel muscle-specific disease genes.

128 ions were concentrated and associated with a specific disease group.

129 Chronic histological damage and specific diseases had additive and independent impact on

130 redict and organize genes most relevant to a specific disease has proven especially important.

131 s shown to harbor HTLV-2 in association with specific diseases has, to date, precluded convincing epi

132 Drugs licensed for human use against specific diseases have proved to be effective in extendi

133 idence of upper and lower GIB related to age-specific disease, higher burden of comorbidity and incre

134 f CD21(low) B cells have been highlighted in specific diseases; however, a systematic comparison of d

135 h HD has historically been viewed as a brain-specific disease, htt is expressed ubiquitously, and rec

136 Moreover, genes associated with specific diseases in humans are also found in flies, som

137 and their relationship to decreased risk of specific diseases in infants.

138 ells offer a new way to recapitulate patient specific diseases in vitro, providing an almost limitles

139 me and may ultimately be useful for treating specific diseases in which PAD2 activity is dysregulated

140 Age group-specific disease incidence rates and abridged life table

141 lamins, are associated with multiple tissue-specific diseases, including Emery-Dreifuss (EDMD2/3) an

142 t to understanding ill health as a result of specific diseases, increasingly defined more by signs th

143 nitratively modified with tissue injury in a specific disease is limited, however.

144 he allergy field is to understand how tissue-specific disease is manifested.

145 of interest, such as those correlating to a specific disease, is critical when analysing flow cytome

146 many examples of novel and African ancestry-specific disease loci that have been discovered.

147 of PrP(Sc) causes a robust, reproducible and specific disease manifestation.

148 nic cells contribute to both generalized and specific disease manifestations.

149 tween cells in mosaic females lead to female-specific disease manifestations.

150 e genetic effects that influence the risk of specific disease manifestations.

151 ulties in provision of appropriate drugs for specific diseases, many other factors contribute to the

152 onses has not been possible due to lack of a specific disease marker.

153 cardiomyocytes to gain insights into patient-specific disease mechanism and pharmacotherapy.

154 ation of miRNAs in HF, shedding light on the specific disease mechanisms differentiating diabetic pat

155 Specific disease mechanisms implicated in childhood arte

156 -like astrocytes presented additional, human-specific disease mechanisms, such as neuronal and mitoch

157 treatments through improved understanding of specific disease mechanisms.

158 these mice may arise through multiple tissue-specific disease mechanisms.

159 Biopharmaceuticals that target specific disease-mediating molecules have advanced our u

160 s been proposed, but the nature of such site-specific disease memory is unknown.

161 Survival and time from diagnosis to specific disease milestones were calculated to assess di

162 ting complex signal integration in a patient-specific disease milieu.

163 d specific cell types is crucial for patient-specific disease modeling and drug testing.

164 nsplantation, drug toxicity testing, patient-specific disease modeling, and even ex vivo gene therapy

165 y testing, cell transplantation, and patient-specific disease modeling.

166 tro and used to generate patient- and tissue-specific disease models.

167 s, suggesting that these two factors are sex-specific disease modifiers and raising the possibility t

168 ients with rheumatoid arthritis (RA) in whom specific disease-modifying antirheumatic drugs (DMARDs)

169 degeneration, suggesting a potential miR-23a-specific disease-modifying effect.

170 evelopment of novel therapeutics, and target specific disease-modifying pathways intrinsic to the ven

171 ing of neurodegenerative diseases increases, specific disease-modifying treatments might become avail

172 hate receptor 2 (S1PR2) as a sex- and strain-specific, disease-modifying molecule that regulates BBB

173 kely reflects the cellular source of IL-6 in specific diseases, much of which may be produced by nonh

174 elevated in mice prone to Th1-mediated organ-specific disease (nonobese diabetic (NOD) and SJL mice)

175 nformation presented is further organized by specific diseases now associated with the microbiota: St

176 But how is a joint-specific disease of autoimmune and inflammatory nature i

177 Glaucoma is a specific disease of the optic nerve and is often more se

178 d be implemented in treatment algorithms for specific diseases of kidney allografts.

179 in estimating the probability or risk that a specific disease or condition is present (diagnostic mod

180 The primary outcome measure was specific disease or diseases stratified by HIV status.

181 ses, which are often specialized to target a specific disease or host organism.

182 Health problems were not focused on specific diseases or limited to survivors with readily i

183 y postreceptor signal regulators involved in specific diseases or organ adaptation, we used an expres

184 logical processes or therapeutic targets for specific diseases or patient types.

185 Most are voluntary and may be organ specific, disease or condition specific, organ and disea

186 tterns of gene expression that contribute to specific disease outcomes are not well understood.

187 reas the N153S does not, indicating mutation-specific disease outcomes.

188 ication of tumour sub-populations that drive specific disease pathologies for the development of ther

189 sera can be used to understand the pregnancy-specific disease pathology in mice and can predict the d

190 proven mechanisms of action interfering with specific disease pathways, and approaches that could be

191 sary for glucose homeostasis, resulting in a specific disease pattern linking chromatin modification

192 Despite these changes, the 263K strain-specific disease phenotype was preserved after passage t

193 ificant function and that JNCL is a mutation-specific disease phenotype.

194 ein domain specificity direct cells toward a specific disease phenotype.

195 evaluated in human blood cells expressing a specific disease phenotype.

196 isease characteristics, molecular markers of specific disease phenotypes and more efficacious treatme

197 on of exhaled breath metabolites with gender-specific disease phenotypes and pharmacokinetics in the

198 an infections, but the mechanisms leading to specific disease phenotypes can be investigated using st

199 sts caution should be taken when attributing specific disease phenotypes to these repeat lengths.

200 ve analysis of gene matrices associated with specific disease phenotypes, therefore allowing screenin

201 te response pathways corresponding to strain-specific disease phenotypes.

202 the vast majority of MDS cases and underlie specific disease phenotypes.

203 may play an important role in TMEV subgroup-specific disease phenotypes.

204 OGGs are often associated with specific disease phenotypes.

205 sult of selective recruitment dictate strain-specific disease phenotypes.

206 nct polymorphic amyloids that exhibit strain-specific disease phenotypes.

207 or identify early signs of efficacy within a specific disease population.

208 e families or cases is dependent on the gene-specific disease prevalence and the sample size.

209 Unless a specific disease process can be identified, what drives

210 screens to identify novel genes involved in specific disease processes and chemical screens to ident

211 omes increasingly sophisticated, focusing on specific disease processes and empirically tested and ef

212 tial measurements of ECM remodeling to these specific disease processes are warranted.

213 tions of NF-kappaB in normal homeostasis and specific disease processes in the intestinal tract.

214 ays not previously identified in the obesity-specific disease profile.

215 development has not been demonstrated, and a specific disease-promoting myeloid cell population has n

216 more precisely identify correlates of virus-specific disease-protective responses.

217 century, epidemiologists have stratified age-specific disease rates by year of birth to better unders

218 evere disease and accumulation of SARS-CoV-2-specific "disease-related" B cell populations.

219 Because they carry specific disease-related RNAs and proteins, practical ap

220 inding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b produc

221 nd may open up new opportunities for patient-specific, disease-relevant research.

222 Some trigger the action of specific disease resistance (R) gene products.

223 Nonrace specific disease resistance 1 (NDR1) is a conserved down

224 This siRNA contributes to RPS2-mediated race-specific disease resistance by repressing PPRL, a putati

225 Race-specific disease resistance in plants is mediated by the

226 sts; they are also the proteins that trigger specific disease resistance in resistant plant hosts.

227 Specific disease resistance of Arabidopsis thaliana agai

228 Many race- or isolate-specific disease resistance responses of plants toward p

229 Gene-for-gene type specific disease resistance that is effective against ri

230 d immunity (ETI) has been implicated in race-specific disease resistance.

231 full-length Oas1b protein confers flavivirus-specific disease resistance.

232 ffector action, the requirement for NON-RACE-SPECIFIC DISEASE RESISTANCE1 (NDR1) is shared.

233 Arabidopsis (Arabidopsis thaliana) NON-RACE-SPECIFIC DISEASE RESISTANCE1 (NDR1), a plasma membrane-l

234 We propose an adjusted, gender-specific disease risk stratification scheme for Middle E

235 iating SN cell type expression profiles with specific disease risk.

236 ncidence (hospitalisation or death) rates of specific diseases, RRs were as follows: pulmonary embolu

237 Within this framework, a specific disease's expression is a consequence of the in

238 ients with severe sepsis and septic shock in specific disease severity subgroups.

239 earch with population changes in the risk of specific diseases should be analyzed.

240 ability to link each recommended medicine to specific diseases, should allow public officials to appl

241 erived human immune cells as well as patient-specific disease signatures in multiple myeloma.

242 -based drug discovery platforms with patient-specific disease signatures, ultimately facilitating the

243 ogy QOL instruments may measure general skin-specific, disease-specific, or condition-specific QOL.

244 ent sets of M-modules that are important for specific disease stage transitions and offer new insight

245 egin to link motor microcircuit pathology to specific disease stages and clinical phenotypes.

246 narrow outcomes such as income, or a single specific disease state, or a measure of positive affect.

247 n such as which genes are overexpressed in a specific disease state.

248 ew information regarding editing patterns in specific disease states and in response to pharmacologic

249 erstanding of NET properties associated with specific disease states and microbial infections.

250 reatment of complement-mediated hemolysis in specific disease states are described.

251 g on children who fulfilled the criteria for specific disease states as defined by the consensus crit

252 of enteral nutrition and their efficacy for specific disease states continue to demonstrate the diff

253 on that accurately and reproducibly identify specific disease states in murine atherosclerosis.

254 iagnostic and therapeutic decision making in specific disease states such as hypertrophic cardiomyopa

255 n detecting pathway networks associated with specific disease states when compared to published pathw

256 ring normal development and are disrupted in specific disease states, particularly in cancer.

257 g the antimicrobial review process to target specific disease states, reassessing the usefulness of c

258 Factors such as patient-specific disease states, resident guideline learning cur

259 costimulatory pathway, they are tailored for specific disease states--abatacept for autoimmune diseas

260 n filament function that results in mutation-specific disease states.

261 activities in normal cellular processes and specific disease states.

262 ables may also aid in outcome prediction for specific disease states.

263 xpression pattern signatures associated with specific disease states.

264 s may provide new therapeutic approaches for specific disease states.

265 litate development of treatments tailored to specific disease subgroups and could potentially enable

266 nt inhibitors either by focusing research to specific disease subpopulations that exhibit greater ben

267 of clinical features reported for each gene-specific disease subtype in the literature and highlight

268 d liver might help us identify patients with specific disease subtypes and select specific microbiota

269 nd the molecular classification of PDAC into specific disease subtypes have all converged to illumina

270 identifying rational therapeutic targets in specific disease subtypes.

271 explanation for the genetic basis of tissue-specific diseases such as AMD and atypical hemolytic ure

272 olecular imaging followed by applications to specific diseases such as Barrett's esophagus and colon

273 opment of new therapeutic approaches for RPE-specific diseases such as certain forms of retinitis pig

274 transplantation, including studies of human-specific diseases such as hepatitis-C, as treatment for

275 screen all newly arriving migrants for some specific diseases (such as tuberculosis) and can be used

276 restricted populations, or been targeted at specific diseases, such as cancer.

277 issues are infected and contribute to tissue-specific diseases, such as encephalitis and dementia in

278 uture routes to understanding the biology of specific disease susceptibility loci.

279 d to be perturbed in DM, and the severity of specific disease symptoms varies among individuals.

280 these measures depend on the recognition of specific disease symptoms, we investigate the relative t

281 the plant's auxin response system to induce specific disease symptoms.

282 Subsequently, specific disease syndromes were discussed in more detail

283 prospects for vaccines that protect against specific disease syndromes.

284 Depending on the specific disease target, there may be one or many cell t

285 s to achieve high levels of drug delivery to specific diseased targets such as tumours.

286 into cardiomyocytes, they model a patient's specific disease, test pharmaceuticals, and potentially

287 later phase trials that assess efficacy in a specific disease that spans adult and pediatric populati

288 ts have evaluated conventional treatments of specific diseases; they are critical but underfunded and

289 of surveillance systems tailored to setting-specific disease transmission dynamics and surveillance

290 vity is anticipated and when relevant to the specific disease type.

291 logically meaningful biomarkers related to a specific disease under study.

292 In the remaining 57 patients (28%), no specific disease was found.

293 ting the total number of persons living with specific diseases, we applied prevalence estimates of th

294 For hundreds of sex- and age-specific diseases, we assessed effects of the DST shifts

295 temporal pattern and age-dependent nature of specific diseases, we find that smallpox is more consist

296 between distantly related grasses to control specific diseases, we identified a maize R gene that rec

297 model of clinical prevention that focuses on specific diseases, well-defined preventive interventions

298 ct relations between vitamin D(3) status and specific diseases while advocating the safest possible m

299 the top down, focusing on the prevalence of specific diseases within a population.

300 than a single disease, the identification of specific diseases within the syndrome would facilitate t